The industry's claimed 'surprised' over the government's approach to the implementation, notably the 'double dipping' on statutory price reductions, appears to confront the significant challenge that it was warned of the risk last year but dismissed any concern. …
The industry was warned last year but dismissed the risk of 'double dipping' on April reductions
October 10, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Vitex opens $250 million pharmaceutical manufacturing facility in Western Sydney
July 6, 2026 - - Latest News -
Early clinical imaging shows Syntara candidate reduces brain inflammation in people at high risk of Parkinson’s
July 6, 2026 - - Australian Biotech -
Widespread use of statins narrows heart-risk gap between overweight and normal-weight adults
July 6, 2026 - - Latest News -
A performative change that still leaves the door open for a response to 'MFN' risk
July 6, 2026 - - Latest News -
New law proposes limiting trade minister's power over PBS concessions
July 6, 2026 - - Latest News -
The 'Dispatched' Podcast - Season 5, Episode 22
July 3, 2026 - - Podcast -
Is that a subtle but meaningful shift conceding the potential need for a response to global realities?
July 3, 2026 -